Post–COVID-19 Infection Remains a Concern in Patients With Cancer
Many questions remain unanswered about COVID-19, and we are now experiencing another problem—postacute sequelae of SARS-CoV-2 infection, also referred to as post–COVID-19 condition or post-COVID syndrome.
Can Just-in-Time Clinical Trials Reduce Disparities in Participation?
August 16th 2022Just-in-time trials are 1 tool capable of rapidly increasing access to clinical trials to develop drugs that treat the diverse and unique tapestry of patients across the United States, especially patients with more diverse racial, ethnic, and socioeconomic backgrounds.
Incorporating Biomarker Testing in Community Cancer Clinics: A Real-World Pilot Study
Although there is tremendous excitement about boundaries of science stretching beyond human imagination, realizing the real-world impact of scientific advancement on the health outcomes of patients provides a reality check on how far we still must go.
Differentiating Pseudoprogression From Hyperprogression in Patients Treated With Immunotherapies
Advances in the field have also led to the recognition of other clinical challenges, including unforeseen observations and complications associated with choosing the sequencing of appropriate therapeutic interventions as well as the management of drug-related complications.
The Role of In-Office Next Generation Sequencing to Advance Precision Medicine in Community Oncology
The goal of precision medicine is to advance medical and scientific discoveries to offer more tailored, precise, and accurate health interventions to maximize the health benefits for patients.
Despite Advances in Precision Medicine, Disparities Persist
November 23rd 2020The goal of precision medicine is to advance medical and scientific discoveries while offering more tailored, precise, and accurate health interventions, thus maximizing health benefits for patients while reducing adverse effects and overall cost of care.
COVID-19 Presents an Opportunity for Precision Medicine to Play Expanded Role in Care
"We recommend following an assessment for patients with cancer and treatment priority determination that would assist in the management of these patients."